PLEN-2 - Communicating COVID-19 Pharmacoepidemiological Research to Patients: Why is it important? How can we do it? What are the implications now and for the future?
8:30 AM – 10:00 AM US Eastern Time
PLEN-2 - Plenary Session: Communicating COVID-19 Pharmacoepidemiological Research to Patients: Why Is It Important? How Can We Do It? what Are the Implications Now and for the Future?
Location: PLEN-2
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
Concurrent Session 3
10:00 AM – 11:30 AM US Eastern Time
CW06 - Concurrent Workshops 3
10:00 AM – 11:30 AM US Eastern Time
WS-06 - From the Individual Through the Health System and Back: The Interdisciplinary Promise and Challenges of Digital Epidemiology for Improved Outcomes (An ISPE Digital Epidemiology SIG Endorsed Symposium)
Location: WS-06
Informatics
10:00 AM – 11:30 AM US Eastern Time
WS-07 - How to Emulate a Target Trial to Study the Effects of Treatments for and During Pregnancy
Location: WS-07
Pregnancy and Lactation
10:00 AM – 11:30 AM US Eastern Time
WS-08 - Lessons for Regulatory Decision-making from Real-world Data Trial Emulation Results
Location: WS-08
Drug Effectiveness
10:00 AM – 11:30 AM US Eastern Time
WS-09 - Methodological Approaches to Evaluating the Safety and Effectiveness of Multi-dose Coronavirus Disease 2019 (COVID-19) Vaccines Series
Location: WS-09
Vaccines
11:45 AM – 1:15 PM US Eastern Time
CW01 - Concurrent Workshops 4
11:45 AM – 1:15 PM US Eastern Time
WS-01 - A Call for ‘environmental Pharmacoepidemiology’: Medications, Global and Local Environments, and Health Outcomes
Location: WS-01
Methods in Pharmacoepidemiology
11:45 AM – 1:15 PM US Eastern Time
WS-02 - Believability of Real-world Evidence (RWE) for Informed Regulatory Decisions
Location: WS-02
Methods in Pharmacoepidemiology
11:45 AM – 1:15 PM US Eastern Time
WS-10 - New Frontiers in Computable Phenotyping for Medical Product Safety Evaluation
Location: WS-10
Methods in Pharmacoepidemiology
11:45 AM – 1:15 PM US Eastern Time
WS-20 - Using Real-world External Controls to Support Drug Approval: An Interactive Framework Using Oncology Trial and Real-world Data
Location: WS-20
Methods in Pharmacoepidemiology
Oral Presentations Session 3
1:45 PM – 3:30 PM US Eastern Time
OP-15 - Pharmacovigilance, Safety End Points, and Potpourri
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Pharmacovigilance, Safety End Points, and Potpourri
Location: OP-15
1:45 PM – 3:30 PM US Eastern Time
OP-15A - The Association Between Bariatric Surgery and Dupuytren Disease: A Cohort Study from Swedish Nationwide Healthcare Registries
Location: OP-15
Rare Disease
1:45 PM – 3:30 PM US Eastern Time
OP-15B - Selective Serotonin Reuptake Inhibitors and the Risk of Type 2 Diabetes Mellitus in Youths
Location: OP-15
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-15C - Comparing the Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib and TNF Inhibitors in Taiwan
Location: OP-15
Pharmacovigilance
1:45 PM – 3:30 PM US Eastern Time
OP-15D - Risk of Type 2 Diabetes Among Children Initiating Anticonvulsant Mood Stabilizers: Application of a Target Trial Approach
Location: OP-15
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-15E - Risk of Diabetic Ketoacidosis with Sodium-glucose transporter-2 Inhibitors Compared to Dipeptidyl peptidase-4 (DPP4) Inhibitors and Sulfonylureas in Patients with Type 2 Diabetes
Location: OP-15
Safety End Points
1:45 PM – 3:30 PM US Eastern Time
OP-15F - Comparable COVID-19 Outcomes with Current Use of GLP-1 Receptor Agonists, DPP-4 Inhibitors or SGLT-2 Inhibitors Among Patients with Diabetes Who Tested Positive for sars-cov-2
Location: OP-15
Disease Epidemiology/Clinical Course
1:45 PM – 3:30 PM US Eastern Time
OP-23 - Thinning the Blood: The Role of Anticoagulation and COVID-19
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Thinning the Blood: The Role of Anticoagulation and COVID-19
Location: OP-23
1:45 PM – 3:30 PM US Eastern Time
OP-23A - Heterogeneity and Temporal Variation in the Management of COVID-19: A Multinational Drug Utilisation Study Including 274,719 Hospitalised Patients From, the United States of America, China, Spain, and South Korea
Location: OP-23
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-23B - Real World Use of Anticoagulation Among Hospitalized Patients with COVID-19 in the United States
Location: OP-23
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-23C - Safety and Effectiveness of Prophylactic Anticoagulation for Prevention of COVID-19 Mortality: A Nationwide Cohort Study of Hospitalised Patients in the US
Location: OP-23
Drug Effectiveness
1:45 PM – 3:30 PM US Eastern Time
OP-23D - Anticoagulants and All-cause Mortality Among Hospitalized COVID-19 Patients
Location: OP-23
Drug Effectiveness
1:45 PM – 3:30 PM US Eastern Time
OP-23E - Use of Cardiovascular and Antidiabetic Drugs During COVID19 Epidemic in France
Location: OP-23
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-23F - Substantial Heterogeneity in the Management of Hospitalized Patient with COVID-19
Location: OP-23
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-25 - Two Hearts Beat as One: Evidence for Cardiovascular Safety from Real World Data and Clinical Trials
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Two Hearts Beat as One: Evidence for Cardiovascular Safety from Real World Data and Clinical Trials
Location: OP-25
1:45 PM – 3:30 PM US Eastern Time
OP-25A - Comparative Risk of Hospitalization for Heart Failure Among Patients with Xanthine Oxidase Inhibitors and Uricosuric Agents
Location: OP-25
Health Economics/Outcomes Research
1:45 PM – 3:30 PM US Eastern Time
OP-25B - Cardiovascular Risk in Users of Mirabegron Relative to Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-interventional, Real-world Data Safety Study
Location: OP-25
Safety End Points
1:45 PM – 3:30 PM US Eastern Time
OP-25C - Use of Low-dose Quetiapine and the Risk of Major Adverse Cardiovascular Events
Location: OP-25
Safety End Points
1:45 PM – 3:30 PM US Eastern Time
OP-25D - Jak Inhibitors and the Risk of Cardiovascular and Venous Thromboembolism Events Among Patients with Rheumatoid Arthritis: A Network Meta-analysis of Clinical Trials
Location: OP-25
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
1:45 PM – 3:30 PM US Eastern Time
OP-25F - Non-adherence and Non-persistence with Direct Oral Anticoagulants Increases the Risk of Stroke: Assessment in Three European Databases
Location: OP-25
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-27 - Validation and Algorithms: Getting the Present and Future Right
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: Validation and Algorithms: Getting the Present and Future Right
Location: OP-27
1:45 PM – 3:30 PM US Eastern Time
OP-27A - Validity of Electronic Health Records-based Measures for COVID-19 Hospitalization and Severe Outcomes
Location: OP-27
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-27B - Death Documentation Lag in COVID-19 Electronic Health Record (EHR) Suggests Caution in Near-real-time Analysis
Location: OP-27
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-27C - Shifting the Traditional Model of Analysing Downloaded Electronic Health Records to the Novel Open-source Analytics Opensafely Platform
Location: OP-27
Informatics
1:45 PM – 3:30 PM US Eastern Time
OP-27D - Use of an EHR to Inform a Claims-based Algorithm to Categorize Inpatient COVID-19 Severity
Location: OP-27
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-27E - Categorization of COVID-19 Severity to Determine Mortality Risk
Location: OP-27
Methods in Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-27F - Development and Validation of an Algorithm to Estimate the Risk of Severe Complications of COVID-19 to Prioritise Vaccination
Location: OP-27
Disease Epidemiology/Clinical Course
1:45 PM – 3:30 PM US Eastern Time
OP-28 - You gave the kids what? International use, policies, and outcomes in pediatric pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
Oral Papers: You Gave the Kids What? International Use, Policies, and Outcomes in Pediatric Pharmacoepidemiology
Location: OP-28
1:45 PM – 3:30 PM US Eastern Time
OP-28A - Early Life Antibiotic Exposure and Incident Chronic Diseases in Childhood
Location: OP-28
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-28B - Antibiotic Prescribing in Children Aged 0–6 Years in Germany: Assessing Regional Variations and Potential Explanations Based on Claims Data
Location: OP-28
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-28C - Prescribed Medicine Use in a Nationwide Sample of Australian Children: Extent of Off-label Use
Location: OP-28
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-28D - General Practitioner Prescribing Trends Among Pediatric Patients in the United Kingdom: 1998-2018
Location: OP-28
Pediatric Pharmacoepidemiology
1:45 PM – 3:30 PM US Eastern Time
OP-28E - Visualizing Inappropriate Antibiotic Use Following Otitis Media in Children in the United States
Location: OP-28
Drug Utilization Research
1:45 PM – 3:30 PM US Eastern Time
OP-28F - Impact of Drug-related Regulations on Codeine Use Among Children in Taiwan: A Nationwide Interrupted Time Series Analysis from 2005 to 2018
Location: OP-28
Pediatric Pharmacoepidemiology
Spotlight Posters 1
3:30 PM – 4:45 PM US Eastern Time
SP01 - Spotlight Posters: Adherence
3:30 PM – 4:45 PM US Eastern Time
SP01 - Spotlight Posters: Adherence
Location: SP01
3:30 PM – 4:45 PM US Eastern Time
SP0K - Impact of Lipid Lowering Therapy Modifications on Medication Adherence in Older Adults
Location: SP01
Health Economics/Outcomes Research
3:30 PM – 4:45 PM US Eastern Time
SP01A - Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon Like Peptide 1 Agonists in a Large Integrated Healthcare System
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01B - Comparing FOLFOX Delivery in Trial and Real-world Populations Using Longitudinal Cumulative Dose
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01C - Low Persistence of Antipsychotic Therapy in Parkinson Disease – Intolerance, Ineffectiveness, or Inertia?
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01D - Trajectories of Oral Budesonide Use in Crohn's Disease Cohort of Tuscan Patients (Italy)
Location: SP01
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP01E - Factors Associated with Adherence to Newly Initiated JAK Inhibitors in Rheumatoid Arthritis Patients
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01F - Pharmacological and Epidemiological Considerations While Constructing Drug Treatment Episodes Using Observational Data Retrospectively Collected: A Simulation Study
Location: SP01
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP01G - Comparison of Measures for Medication Adherence of Antihypertensive Drugs Using National Health Insurance Claims Data
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01H - Adherence and Associated Factors of Treatment Regimen in Drug-susceptible tuberculosis Patients
Location: SP01
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP01J - Antihypertensive and Lipid-lowering Drugs Usage After Primary Stroke
Location: SP01
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP02 - Spotlight Posters: ASPEN
3:30 PM – 4:45 PM US Eastern Time
SP02 - Spotlight Posters: ASPEN
Location: SP02
3:30 PM – 4:45 PM US Eastern Time
SP02A - Tramadol Dominating the Longitudinal Trajectories of Chronic Opioid Prescribing and Co-medication in Non-cancer Patients in Taiwan
Location: SP02
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP02B - Active Surveillance of Hemovigilance in a Tertiary Care Teaching Hospital: A Developing Country Scenario
Location: SP02
Pharmacovigilance
3:30 PM – 4:45 PM US Eastern Time
SP02C - Active Surveillance of Materiovigilance in a Tertiary Care Teaching Hospital: An Initiation of Clinical Pharmacist
Location: SP02
Medical Devices
3:30 PM – 4:45 PM US Eastern Time
SP02D - The Risk of Serious Infection in Rheumatoid Arthritis Patients Receiving Tocilizumab Compared with Tumor Necrosis Factor Inhibitors in Korea
Location: SP02
Biologics/Biosimilars
3:30 PM – 4:45 PM US Eastern Time
SP02E - Use of Antipsychotics and Cholinesterase Inhibitors and the Risk of Falls and Fractures
Location: SP02
Geriatric Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP02F - The Risk of Seizures Associated with the Use of Tramadol: A Nationwide Case-case-time-control Study
Location: SP02
Safety End Points
3:30 PM – 4:45 PM US Eastern Time
SP02G - Adherence to Medication: Patient Reported Facilitators and Barriers
Location: SP02
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP02H - The Association Between Influenza Vaccination and the Risk of Bell's Palsy in the Korean Elderly
Location: SP02
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP03 - Spotlight Posters: Biologics
3:30 PM – 4:45 PM US Eastern Time
SP03A - Spotlight Posters: Biologics
Location: SP03
3:30 PM – 4:45 PM US Eastern Time
SP03B - Colonoscopy Use After Treatment Initiation in US Commercially Insured Patients with Inflammatory Bowel Disease, 2013-2018
Location: SP03
Biologics/Biosimilars
3:30 PM – 4:45 PM US Eastern Time
SP03C - Incidence of Inpatient Constipation Among Migraine Patients Treated with Erenumab: A Retrospective Cohort Study in a US Electronic Health Record Database
Location: SP03
Safety End Points
3:30 PM – 4:45 PM US Eastern Time
SP03E - What Happened to Rheumatoid Arthritis Patients Who Stopped Biologic or Targeted Synthetic Disease Modifying Antirheumatic Therapy?
Location: SP03
Biologics/Biosimilars
3:30 PM – 4:45 PM US Eastern Time
SP03F - Utilisation and Treatment Patterns of Medicines to Manage Relapsing Remitting Multiple Sclerosis: Implications for Pharmacovigilance
Location: SP03
Drug Utilization Research
3:30 PM – 4:45 PM US Eastern Time
SP03G - Outpatient Transfusions and Occurrence of Febrile Non-hemolytic Transfusion Reactions Among U.S. Medicare Beneficiaries, Ages 65 and Older, During 2011-2018: Utility of Real-world Data
Location: SP03
Biologics/Biosimilars
3:30 PM – 4:45 PM US Eastern Time
SP03H - Direct Health Care Costs Among Patients with Rheumatoid Arthritis Before and After the Initiation of Treatment with Jaki in Tuscany: The LEONARDO Study
Location: SP03
Health Economics/Outcomes Research
3:30 PM – 4:45 PM US Eastern Time
SP03J - Risk of Serious Infection in Patients with Psoriasis: A Cohort Study of 44,239 Biologic-naïve Patients Using the French National Health Data System
Location: SP03
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP03K - Disease Severity and Outcomes Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic: Real-world US Experience with Sarilumab from the ACR RISE Registry
Location: SP03
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP04 - Spotlight Posters: BRACE
3:30 PM – 4:45 PM US Eastern Time
SP04 - Spotlight Posters: BRACE
Location: SP04
3:30 PM – 4:45 PM US Eastern Time
SP04A - A Scoping Review of Key Use Cases for Artificial Intelligence to Reduce the Frequency of Adverse Drug Events
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04B - Awareness of Isotretinoin Use and Saudi FDA Pregnancy Prevention Program in Riyadh, Saudi Arabia: A Cross-sectional Study Among Female Patients
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04C - Evaluating Physician Knowledge of Risks and Safe Use of Rivaroxaban
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04D - Challenges and Recommendations in Understanding National Guidance and Marketing Authorization Holder Experiences for Implementing Additional Risk Minimization Measures in the European Union and the United Kingdom
Location: SP04
Pharmacovigilance
3:30 PM – 4:45 PM US Eastern Time
SP04E - Efficacy and Safety of Isoniazid Preventive Therapy (IPT) in People Living with Hiv: A Systematic
review and Meta-analysis
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04F - Effectiveness of Direct Healthcare Professional Communication for Concentrated Insulin Lispro (U-200 Kwikpen) in France, Germany, and Sweden
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04G - Dermatologists Awareness and Compliance with Saudi FDA Isotretinoin Pregnancy Prevention Program in Saudi Arabia: A Cross-sectional Study
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04H - Saudi Fda-approved Risk Minimization Measures: A Descriptive Overview
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP04J - Longitudinal Evaluation of U.S. REMS Program Modifications (2008–2020)
Location: SP04
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP05 - Spotlight Posters: Cancer
3:30 PM – 4:45 PM US Eastern Time
SP05 - Spotlight Posters: Cancer
Location: SP05
3:30 PM – 4:45 PM US Eastern Time
SP05A - Outcomes in Patients (pts) with Advanced Basal Cell Carcinoma (aBCC) Who Discontinued First-line (1L) Hedgehog Inhibitors (HHI) Systemic Treatment (Tx) in a US Community Oncology Setting: A Retrospective Observational Study
Location: SP05
Health Economics/Outcomes Research
3:30 PM – 4:45 PM US Eastern Time
SP05B - Nonsteroidal Anti-inflammatory Drug Use and Skin Cancer Risk: A Prospective Cohort Study
Location: SP05
Disease Epidemiology/Clinical Course
3:30 PM – 4:45 PM US Eastern Time
SP05C - Non-interventional Post-authorization Safety Studies and Post-authorization Effectiveness Studies for Oncology Drugs: A Systematic Review
Location: SP05
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
3:30 PM – 4:45 PM US Eastern Time
SP05D - Lessons Learned in Predicting Gastric Cancer Survival Using Machine Learning
Location: SP05
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP05E - Real World Progression-free Survival in Patients with Advanced or Metastatic Urothelial Cancer Treated with First-line Platinum-based Chemotherapy
Location: SP05
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP05F - DNA Mismatch Repair and Microsatellite Instability in Colorectal Tumors: An Observational Study in the Veterans Affairs Health Care System
Location: SP05
Health Economics/Outcomes Research
3:30 PM – 4:45 PM US Eastern Time
SP05G - Comparison of the Risk of Cardiovascular Outcomes in Novel Hormonal Agents in Metastatic Castration-resistant Prostate Cancer
Location: SP05
Safety End Points
3:30 PM – 4:45 PM US Eastern Time
SP06 - Spotlight Posters: Comparative Effectiveness Research
3:30 PM – 4:45 PM US Eastern Time
SP06 - Spotlight Posters: Comparative Effectiveness Research
Location: SP06
3:30 PM – 4:45 PM US Eastern Time
SP06A - Comparative Effectiveness and Safety of Apixaban versus Rivaroxaban Among Patients with Non-valvular Atrial Fibrillation and Liver Disease: A Population-based Cohort Study
Location: SP06
Drug Effectiveness
3:30 PM – 4:45 PM US Eastern Time
SP06B - Misclassification of Obesity in Claims Data – Are Assumptions About Non-differential Misclassification Warranted?
Location: SP06
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP06E - Use of Negative Control Outcomes to Detect Mismeasured Confounders in Administrative Data
Location: SP06
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP06F - Perioperative Gabapentinoids and Risk of Postoperative Chronic Opioid Use Among Older Adults Undergoing Total Knee or Hip Arthroplasty
Location: SP06
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP06G - Best Practice Recommendations for the Design and Analyses of Pragmatic Clinical Trials: A Modified Delphi Method Study
Location: SP06
Drug Effectiveness
3:30 PM – 4:45 PM US Eastern Time
SP06H - Simulation-based Evaluation of Index Date Selection Methods with External Controls
Location: SP06
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07 - Spotlight Posters: Databases
3:30 PM – 4:45 PM US Eastern Time
SP07 - Spotlight Posters: Databases
Location: SP07
3:30 PM – 4:45 PM US Eastern Time
SP07A - Information on the Socioeconomic Status in the German Pharmacoepidemiological Research Database: Completeness and Proof-of-concept Analysis
Location: SP07
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP07B - Novel Use of Harmonized Data Quality Indicators in Long-term Safety Studies Using Multiple Sclerosis Registries: Approach in CLARION Study
Location: SP07
miscellaneous
3:30 PM – 4:45 PM US Eastern Time
SP07C - Performance of Different Definitions for COVID-19 Infection Across European Databases
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07D - Exposure Misclassification in Pharmacoepidemiology: Sources and Relative Impact
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07E - Validity of ICD-10 Heart Failure Administrative Codes Among the Elderly in the United States
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07F - A Cookbook for Estimating Treatment Duration from Databases of Routinely Collected Electronic Health Data Participating in Multi-source Studies
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP07G - Validation of Acute Outcomes Among Patients with Type 2 Diabetes Mellitus in the Clinical Practice Research Datalink
Location: SP07
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08 - Spotlight Posters: Digital Epidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08 - Spotlight Posters: Digital Epidemiology
Location: SP08
3:30 PM – 4:45 PM US Eastern Time
SP08A - Who Will Develop Diabetes? A 5-year Risk Prediction Model for Antidiabetic Treatment Initiation in Individuals with hba1c-defined Prediabetes
Location: SP08
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08B - Development of a Tool for Detecting Patient-level Symptoms in Relation with Medications Using Disease Blogs on the Internet
Location: SP08
Pharmacovigilance
3:30 PM – 4:45 PM US Eastern Time
SP08C - Comparing Two Geographic Sources of Patient Generated Health Data (PGHD) in a COVID-19 Registry (CARE): UK and US Symptomatology
Location: SP08
Informatics
3:30 PM – 4:45 PM US Eastern Time
SP08D - Use of a Mobile App to Capture Supplemental Health Information During Pregnancy: Implications for Clinical Research
Location: SP08
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08E - Unpicking the Tangled Symptomatology of COVID19 Using an Interpretable Clustering Methodology
Location: SP08
Informatics
3:30 PM – 4:45 PM US Eastern Time
SP08F - Development and Validation of Real-world Prediction Models to Identify Individuals with Undiagnosed NASH
Location: SP08
Methods in Pharmacoepidemiology
3:30 PM – 4:45 PM US Eastern Time
SP08G - Use of a Natural Language Processing-based Approach to Extract Depression Symptom Severity and Suicide Ideation from Clinical Notes to Support Depression Research
Location: SP08
Informatics
Spotlight Posters 2
5:15 PM – 6:30 PM US Eastern Time
SP09 - Spotlight Posters: Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP09 - Spotlight Posters: Drug Utilization Research
Location: SP09
5:15 PM – 6:30 PM US Eastern Time
SP09A - Impact of COVID-19 Outbreak on Anticoagulants Utilization: A Real-word Drug-utilization Study Based on Tuscany Healthcare Administrative Databases
Location: SP09
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP09B - Target Blood Pressure Levels and the Risk of Major Adverse Cardiovascular Events Among Patients with Hypertension at Low Cardiovascular Disease Risk
Location: SP09
Disease Epidemiology/Clinical Course
5:15 PM – 6:30 PM US Eastern Time
SP09C - Factors Associated with Initiation of Oral vs. Injectable Disease Modifying Therapies Among Multiple Sclerosis Patients: A Machine Learning Approach
Location: SP09
Informatics
5:15 PM – 6:30 PM US Eastern Time
SP09D - Drug Utilization Research in Africa: Key Research Challenges
Location: SP09
Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP09E - The Impact of Regulatory Restrictions on the Use of Pregabalin: An Interrupted Time-series
Location: SP09
Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP10 - Spotlight Posters: Drug-Drug Interaction
5:15 PM – 6:30 PM US Eastern Time
SP10 - Spotlight Posters: Drug-drug Interaction
Location: SP10
5:15 PM – 6:30 PM US Eastern Time
SP10A - Drug Utilization and Prescribing Pattern of Concomitant Use of Enzalutamide and Anticoagulation
Location: SP10
Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP10B - Opioid Drug-drug-drug Interactions and Unintentional Traumatic Injury: Screening to Detect Three-way Drug Interaction Signals
Location: SP10
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP10C - Oral Contraceptive Failures in the Presence of a Drug-drug Interaction – Does Progestin Type Matter?
Location: SP10
Drug Effectiveness
5:15 PM – 6:30 PM US Eastern Time
SP10D - Concomitant Use of Direct Oral Anticoagulants and Antiplatelet Agents and the Risk of Major Bleeding and Death Among Patients with Venous Thromboembolism: Preliminary Results of a Population-based Multinational Cohort Study
Location: SP10
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP10E - Calcium Channel Blockers Used Concomitantly with Insulin Secretagogues and Serious Hypoglycemia
Location: SP10
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP10F - Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-based Screening Study
Location: SP10
Safety End Points
5:15 PM – 6:30 PM US Eastern Time
SP10G - COLCHICINE AND cyp3a4/p-gp INHIBITORS INTERACTION SIGNAL DETECTION USING FAERS
Location: SP10
Pharmacovigilance
5:15 PM – 6:30 PM US Eastern Time
SP10H - Acute Generalized Exanthematous Pustulosis (AGEP): Exploratory Analysis on Drug Combinations
Location: SP10
Pharmacovigilance
5:15 PM – 6:30 PM US Eastern Time
SP10J - Risk of Major Bleeding Associated with Concomitant Use of Selective Serotonin Reuptake Inhibitors and Oral Anticoagulants: Systematic Review and Meta-analysis
Location: SP10
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP11 - Spotlight Posters: Genomics
5:15 PM – 6:30 PM US Eastern Time
SP11 - Spotlight Posters: Genomics
Location: SP11
5:15 PM – 6:30 PM US Eastern Time
SP11A - Quantifying Concordance Between Electronic Health Record (EHR) and Comprehensive Genomic Profiling (CGP) Biomarker Status in a Linked Clinico-genomic Database (CGDB)
SP11D - Identification of Sex-specific Genetic Associations with Response to Opioid Analgesics: A Pharmacogenomics Wide Association Study Using the Mayo Clinic RIGHT Protocol
Location: SP11
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP11E - FDA regulatory routes and clinical post-marketing requirements for personalized medicines
SP12B - Potentially Inappropriate Medication Use and Time to Dementia: Does Dose Matter?
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12C - Opioid Utilization Among Older Adults in All Nordic Countries 2009-2018
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12D - Social Determinants of Health Status Trajectories in Older Adults - A National Panel Based Longitudinal Study
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12E - Postoperative Safety of Tramadol Among Older Adults Following Total Hip and Knee Arthroplasty
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12F - Potential Over-treatment and Over-testing Among Older Adults with Type-ii Diabetes in Canada: An Observational Retrospective Cohort Study
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12G - Longitudinal Patterns of Anticholinergic and Sedative Drug Load Among Older Adults
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12H - No Differential Risk of Cutaneous Small Vessel Vasculitis with Oral Anticoagulant Use Among Patients with Atrial Fibrillation
Location: SP12
Disease Epidemiology/Clinical Course
5:15 PM – 6:30 PM US Eastern Time
SP12J - Beta-adrenoceptor Antagonists and Risk of Parkinson’s Disease: Meta-analysis of Pharmacoepidemiological Studies
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP12K - Patterns of Antidementia and Antipsychotic Medication Use Before and After Nursing Home Admission Among Residents with Alzheimer’s Disease
Location: SP12
Geriatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP13 - Spotlight Posters: Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13 - Spotlight Posters: Medical Devices
Location: SP13
5:15 PM – 6:30 PM US Eastern Time
SP13A - Epidemiology of Skin Event Rates Among Users of Pumps for the Subcutaneous Administration of Drugs for Chronic Conditions Based upon the United Kingdom (UK) Clinical Practice Research Datalink (CPRD) GOLD
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13B - Real-world Safety and Efficacy of Same-day Discharge After Catheter Ablation for Atrial Fibrillation
Location: SP13
Health Economics/Outcomes Research
5:15 PM – 6:30 PM US Eastern Time
SP13C - The Associations Between Bariatric Surgery and Hip or Knee Arthroplasty, and Hip or Knee Osteoarthritis: A Cohort Study from Swedish Nationwide Healthcare Registries
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13D - Trends of Transcatheter Left Atrial Appendage Occlusion for Stroke Prevention in Atrial Fibrillation vs. the Use of Oral Anticoagulants
Location: SP13
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP13E - Population Testing for COVID-19: An Exemplary Approach for Ruling out False Positive Results
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13F - EXOGEN Mitigates Risk of Fifth Metatarsal Fracture Nonunion: Results of a Novel Real-world Clinical Study
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13G - Innovative Linkage of Device-generated Data to Electronic Medical Records
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13H - Association of Sex with Risk of 2-year Revision for Patients Undergoing Total Hip Arthroplasty
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13J - Completeness of 1-year Patient Follow-up in 3 Healthcare System Electronic Health Record Systems
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP13K - Real World Utilization of Implantable Cardioverter-defibrillators by Care Setting Among Older Heart Failure Patients in the United States
Location: SP13
Medical Devices
5:15 PM – 6:30 PM US Eastern Time
SP14 - Spotlight Posters: Medications in Pregnancy and Lactation
5:15 PM – 6:30 PM US Eastern Time
SP14 - Spotlight Posters: Medications in Pregnancy and Lactation
Location: SP14
5:15 PM – 6:30 PM US Eastern Time
SP14A - Use of Interrupted Time-series Analysis to Characterize Antibiotic Prescription Fills Across Pregnancy – a Norwegian Nation-wide Cohort Study
Location: SP14
Pregnancy and Lactation
5:15 PM – 6:30 PM US Eastern Time
SP14C - Do Pregnant Women Use Pharmacological Treatment as Prescribed?
Location: SP14
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP14E - Risky Drug Prescribing in 1.8 Million French Pregnant Women: A Nationwide Study Based on Two Risk Classification Systems
Location: SP14
Pregnancy and Lactation
5:15 PM – 6:30 PM US Eastern Time
SP14F - The Use of Type 2 Diabetes Mellitus Medications During Pregnancy in the United States
Location: SP14
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP14G - Women of Reproductive Age in the COVID-19 Active Research Experience (CARE) Registry
Location: SP14
Pregnancy and Lactation
5:15 PM – 6:30 PM US Eastern Time
SP14H - Prenatal Exposure to Teratogenic Medications in the Era of Risk Evaluation and Mitigation Strategies (REMS)
Location: SP14
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
5:15 PM – 6:30 PM US Eastern Time
SP15 - Spotlight Posters: Pediatrics
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP15 - Spotlight Posters: Pediatrics
Location: SP15
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP15A - Risk of Serious Skin and Subcutaneous Tissue Disorders for Nimesulide Among the Pediatric Population: A Jeopardy Identified Through the Analysis of Global Individual Case Safety Reports
Location: SP15
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP15B - Psychiatric and Neurologic Diagnoses in Children on Psychotropic Treatment, a Real-world Data Study from Catalonia (Spain)
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15C - Treatment for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of Poisoning in Children and Adolescents
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15D - Persistent High Level of Paediatric Outpatient Prescriptions in France Between 2010 and 2019: A Nationwide Population-based Study
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15E - Early-life Infection and Antiinfectives Exposure and Prevalence of Overweight and Obesity in Danish Children
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15F - Scandinavian Discrepancies in Use of Hypnotic Drugs Among Children, Adolescents, and Young Adults
Location: SP15
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP15G - Timing of Congenital Malformation Diagnosis Relative to Delivery Date in a Commercially Insured Population of Pregnant Women and Infants
Location: SP15
Pediatric Pharmacoepidemiology
5:15 PM – 6:30 PM US Eastern Time
SP15H - Children’s Relative Age and Medicine Treatment for Attention-deficit/hyperactivity Disorder (ADHD) Across Australian Jurisdictions with Different School Enrolment Policies
Location: SP15
Drug Utilization Research
5:15 PM – 6:30 PM US Eastern Time
SP16 - Spotlight Posters: Rare Diseases
5:15 PM – 6:30 PM US Eastern Time
SP16 - Spotlight Posters: Rare Diseases
Location: SP16
5:15 PM – 6:30 PM US Eastern Time
SP16A - Feasibility Assessment of Claims Databases for Pregnancy Outcomes
Location: SP16
Safety End Points
5:15 PM – 6:30 PM US Eastern Time
SP16B - A View into the Tay Sachs Variants’ Populations Using the GM2 Disease Registry
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16C - Prevalence of Mammary Paget’s Disease in Urban China in 2016
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16D - Burden of Comorbidities Among Adults with Concurrent Obesity and Heart Failure with Preserved Ejection Fraction
Location: SP16
Disease Epidemiology/Clinical Course
5:15 PM – 6:30 PM US Eastern Time
SP16E - Incidence of Steroid-related Damage in Korean Patients with Systemic Lupus Erythematosus, Compared to General Population, 2002-2015 : A Retrospective Cohort Study
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16F - Prevalence of Focal Segmental Glomerular Sclerosis (FSGS) in the United States: Results from Electronic Healthcare Records Using Clinically Defined Algorithms
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16G - Characteristics of a Prevalent SMA Population Drawn from a Patient Registry Network
Location: SP16
Rare Disease
5:15 PM – 6:30 PM US Eastern Time
SP16H - Incidence and Prevalence of Rhabdomyolysis in Patients with Type 2 Diabetes in the US
Location: SP16
Disease Epidemiology/Clinical Course
5:15 PM – 6:30 PM US Eastern Time
SP17 - Spotlight Posters: Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17F - Spotlight Posters: Drug Utilization Research
Location: SP17
5:15 PM – 6:30 PM US Eastern Time
SP17 - The Effect of Prioritization and Second Dose Interval Choice on the Effectiveness of COVID-19 Vaccination in Europe: An Agent-based Cohort Model
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17A - Seasonal Patterns in Vaccine Administration and Outcome Occurrence – a Potential Source of Artifact in Self-controlled Safety Study Designs
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17B - Pfizer-biontech Coronavirus Vaccine and the Risk of Anaphylaxis
Location: SP17
Pharmacovigilance
5:15 PM – 6:30 PM US Eastern Time
SP17C - New-onset Autoimmune Disease (AID) Detection and Validation in Healthcare Databases
Location: SP17
Safety End Points
5:15 PM – 6:30 PM US Eastern Time
SP17D - Anogenital Warts and the Introduction of the Quadrivalent HPV Vaccine Program in Manitoba, Canada
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17E - A Descriptive Retrospective Cohort Study to Establish Rates for Safety Outcomes of Interest (SOI) in Vaccine Development Programs
Location: SP17
miscellaneous
5:15 PM – 6:30 PM US Eastern Time
SP17G - Assessment of Thyroiditis Risk Associated with HPV Vaccination Among Girls Aged 9-18 Years: A Time-varying Cohort Study
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17H - The Safety and Immunologic Effectiveness of the Live Varicella Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy: A Randomized Controlled Trial
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17J - Impact of 2011/2012 ACIP Maternal Pertussis Vaccination Recommendations on Infant Pertussis Mortality in the US
Location: SP17
Vaccines
5:15 PM – 6:30 PM US Eastern Time
SP17K - Validity of Claims-based Algorithms to Identify Patients with Test-positive Influenza
Location: SP17
Methods in Pharmacoepidemiology
Lightning Session 3
6:45 PM – 7:45 PM US Eastern Time
L-3 - Lightning Session 3
6:45 PM – 7:45 PM US Eastern Time
Lightning Session 3
Location: L-3
6:45 PM – 7:45 PM US Eastern Time
L-3A - Gender Differences in Valproic Acid Use for Approved Indications in the United States (2017-2018) – an Opportunity for Risk Mitigation?
Location: L-3
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
6:45 PM – 7:45 PM US Eastern Time
L-3B - Missingness in Real World Data Submitted for Regulatory Decision-making: Eastern Cooperative Oncology Group Performance Status Case Study
Location: L-3
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
6:45 PM – 7:45 PM US Eastern Time
L-3C - Association of Statin Use with Dry Eye Disease
Location: L-3
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
6:45 PM – 7:45 PM US Eastern Time
L-3D - A New Analytic Tool for Interrupted Times Series Analysis to Assess the Impact of FDA Regulatory Actions
Location: L-3
Methods in Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3D - Birth Prevalence of Phenylalanine Hydroxylase Deficiency: A Systematic Literature Review and Meta-analysis
Location: L-3
Disease Epidemiology/Clinical Course
6:45 PM – 7:45 PM US Eastern Time
L-3E - Use of Last Clinical Activity Date in Overall Survival Analysis with Real World Data
Location: L-3
Methods in Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3F - Distinguishing Death from Disenrollment in Claims Data Using a Readily Implemented Machine Learning Algorithm
Location: L-3
Methods in Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3G - Development and Validation of Case-finding Algorithms to Identify Prosthetic Joint Infections After Total Knee Arthroplasty
Location: L-3
Methods in Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3H - Analytical Enhancements in Kentucky’s Drug Overdose Mortality Surveillance: Rapid Monitoring of Trends and Decedents’ Recent Controlled Substance Prescription History
Location: L-3
Drug Utilization Research
6:45 PM – 7:45 PM US Eastern Time
L-3J - Measuring Mental Health Prescribing Safety Indicators in UK Primary Care
Location: L-3
Drug Utilization Research
6:45 PM – 7:45 PM US Eastern Time
L-3K - Pediatric Off-label Antipsychotic Use for Attention-deficit/hyperactivity Disorder: A Time-to-event Analysis
Location: L-3
Pediatric Pharmacoepidemiology
6:45 PM – 7:45 PM US Eastern Time
L-3M - Temporal Effect in Real-world-evidence for Randomized-clinical-trials
Location: L-3
Informatics
6:45 PM – 7:45 PM US Eastern Time
L-3N - The Risk of Melanoma with Rasagiline Compared with Other Antiparkinsonian Medications: A Retrospective Cohort Study in the United States Medicare Database
Location: L-3
Safety End Points
6:45 PM – 7:45 PM US Eastern Time
L-3P - Risk of Major Cardiovascular Event in Jak Inhibitor Treated Patients: Analysis of a National Claim Database
Location: L-3
Biologics/Biosimilars
Plenary 2 - Repeat
8:00 PM – 9:30 PM US Eastern Time
PLEN-2B - REPEAT: Communicating COVID-19 Pharmacoepidemiological Research to Patients: Why is it important? How can we do it? What are the implications now and for the future?
8:00 PM – 9:30 PM US Eastern Time
PLEN-2B - REPEAT: Communicating COVID-19 Pharmacoepidemiological Research to Patients: Why Is It Important? How Can We Do It? what Are the Implications Now and for the Future?
Location: PLEN-2B
Benefit-Risk Assessment, Communication, and Evaluation (BRACE)
